Momenta Pharmaceuticals Appoints Corey N. Fishman to Board of Directors
September 23 2016 - 8:00AM
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology
company specializing in the characterization and engineering of
complex drugs, today announced the appointment of Corey N. Fishman
to its Board of Directors effective September 22, 2016. Mr. Fishman
currently serves as Chief Executive Officer of Iterum Therapeutics
Limited, a clinical-stage pharmaceutical company developing
differentiated anti-infectives for combatting multi-drug resistant
pathogens.
“We are very pleased to welcome Corey to
Momenta’s Board of Directors at this important stage in our
company’s development and growth,” said Craig Wheeler, President
and CEO, Momenta Pharmaceuticals. “Corey is a seasoned
pharmaceutical industry executive with a unique combination of
commercial, operations, finance and business development expertise.
His extensive experience will be a great asset to our Company as we
continue to advance our pipeline of complex generic, biosimilar and
novel drug candidates toward commercialization.”
Mr. Fishman has served as Chief Executive
Officer of Iterum Therapeutics Limited since its founding in late
2015. Previously he served as Chief Financial and Chief Operating
Officer of Durata Therapeutics, Inc. where he managed a successful
IPO and secondary offering, and led the negotiation and sale of the
Company to Actavis plc. Prior to Durata, Mr. Fishman served as
Chief Financial Officer of Ganic Pharmaceuticals, Inc., a Warburg
Pincus Company, and served in several leadership roles, including
Chief Financial Officer, at MedPointe Healthcare, Inc. Mr. Fishman
holds a BA in Economics from the University of Illinois at
Urbana-Champaign and an MSM in Finance from the Krannert School of
Management at Purdue University.
About Momenta
Momenta Pharmaceuticals is a biotechnology
company specializing in the detailed structural analysis of complex
drugs and is headquartered in Cambridge, MA. Momenta is
applying its technology to the development of generic versions of
complex drugs, biosimilar and potentially interchangeable
biologics, and to the discovery and development of novel
therapeutics for autoimmune indications.
To receive additional information about Momenta,
please visit the website at www.momentapharma.com, which does
not form a part of this press release.
Our logo, trademarks, and service marks are the
property of Momenta Pharmaceuticals, Inc. All other trade names,
trademarks, or service marks are property of their respective
owners.
Forward Looking Statements
Statements in this press release regarding
management's future expectations, beliefs, intentions, goals,
strategies, plans or prospects, are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, including but not limited to statements about Mr. Fishman
benefitting the Company; advancing our product pipeline; and
bringing multiple products to market in the coming years.
Forward-looking statements may be identified by words such as
"continue," "will" and other similar words or expressions, or the
negative of these words or similar words or expressions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors, including those referred to under
the section "Risk Factors" in the Company's Quarterly Report on
Form 10-Q for the month ended June 30, 2016, filed with the
Securities and Exchange Commission, as well as other documents that
may be filed by the Company from time to time with the Securities
and Exchange Commission. As a result of such risks, uncertainties
and factors, the Company's actual results may differ materially
from any future results, performance or achievements discussed in
or implied by the forward-looking statements contained herein. The
Company is providing the information in this press release as of
this date and assumes no obligations to update the information
included in this press release or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
INVESTOR CONTACT:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com
MEDIA CONTACT:
Karen Sharma
MacDougall Biomedical Communications
1-781-235-3060
Momenta@macbiocom.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2023 to Apr 2024